Ad Hoc Policy advisory SAGE Working Group on influenza A(H1N1) vaccines (April 2009 to April 2010)
Terms of Reference
- Provide technical advice and support to the WHO Secretariat on identification of essential evidence gaps to inform potential recommendations on the use of Influenza A(H1N1) vaccines, and on possible avenues to acquire priority missing information.
- Facilitate a SAGE review and recommendation on the potential use of Influenza A(H1N1) vaccines (e.g. target populations, target age groups, product formulation, and post-market surveillance).
- David Salisbury, Chair
- Jon Abramson
- Supamit Chunsuttiwat
- Nancy Cox, Centers for Disease Control and Prevention, USA
- Neil Ferguson, Imperial College, UK
- Teeranart Jivapaisarnpong, Ministry of Public Health, Thailand
- Paul-Henri Lambert, Centre Médical Universitaire, Switzerland
- Johannes Loewer, Paul-Ehrlich Institut, Germany
- Karen Midthun, WHO Global Advisory Committee on vaccine Safety, Center for Biologics Evaluation and Research, USA
- Phillip Minor, WHO Expert Committee on Biological Standardization, National Institute for Biological Standards and Control, UK
- Albert Osterhaus, Erasmus MC, Netherlands
- Stefania Salmaso, WHO Global Advisory Committee on vaccine Safety, Istituto Superiore di Sanità, Italy
- Peter Smith, WHO Global Advisory Committee on vaccine Safety, London School of Hygiene and Tropical Medicine, UK
- Marie-Paule Kieny
- Philippe Duclos
DECLARATION OF INTERESTS FOR WHO EXPERTS
All members completed a declaration of interest. Only two members reported any interests.
Dr Neil Ferguson
Dr Neil Ferguson reported receiving small consultancy fees from Baxter, GlaxoSmithKline and Roche for serving on scientific advisory boards and presenting at symposiums. He also received limited amount of consultancy fees from insurance companies (Swiss Re, RMS Ltd.,) and Serco Ltd., a logistics company for advice on pandemic risk and planning. These payments occurred prior to 2008.
Professor Albert Osterhaus
Professor Albert Osterhaus is employed by both Erasmus MC (0.8 full time equivalent) and Viroclinics Biosciences BV (0.2 full time equivalent). Erasmus MC is receiving major grant support from the European Commission and Dutch National Genomics to contribute to countering the public health threat caused by new and emerging infectious diseases in Europe and for development of novel intervention strategies against respiratory viral infections respectively. He holds share certificates of Viroclinics Biosciences BV (9.9%) and holds minority shares in Isoconova AB. Previously he held share certificates with Coronovative. He is also Chairman of the European Scientific Working Group on Influenza, an independent group of European scientists promoting the study of influenza.
Last reviewed: 6 July 2010
Last reviewed: 6 July 2010